SecSonar.com

DexCom, Inc. (DXCM)

DexCom, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

DexCom, Inc. (DXCM) is a Medical - Devices company based in US with a market capitalization of $28.4B. Revenue grew 15.6% year-over-year and the company generated $1.1B in free cash flow. This page tracks DXCM's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 10.2K employees · IPO Apr 14, 2005

Valuation

Valuation & price

$61.63 · as of May 17, 2026 · -31.2% vs 52w high

29.9

P/E ratio

Latest-FY diluted EPS

10.33

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$89.35$72.09$54.84Jul 25Dec 25Jul 26Jul 7, 25$82.94Jul 9, 25$84.87Jul 11, 25$83.37Jul 15, 25$84.78Jul 17, 25$84.10Jul 21, 25$84.03Jul 23, 25$86.43Jul 25, 25$88.99Jul 29, 25$89.35Jul 31, 25$80.77Aug 4, 25$76.25Aug 6, 25$76.40Aug 11, 25$77.85Aug 13, 25$79.96Aug 15, 25$80.95Aug 19, 25$80.90Aug 21, 25$80.62Aug 25, 25$75.96Aug 27, 25$76.38Aug 29, 25$75.34Sep 3, 25$78.92Sep 5, 25$80.51Sep 9, 25$78.40Sep 11, 25$76.00Sep 16, 25$76.55Sep 18, 25$75.78Sep 22, 25$69.51Sep 24, 25$67.50Sep 26, 25$67.10Sep 30, 25$67.29Oct 2, 25$66.44Oct 6, 25$66.36Oct 8, 25$67.78Oct 10, 25$65.12Oct 14, 25$66.21Oct 16, 25$66.33Oct 21, 25$69.75Oct 23, 25$71.06Oct 27, 25$70.63Oct 29, 25$68.18Oct 31, 25$58.22Nov 4, 25$61.18Nov 6, 25$58.02Nov 10, 25$54.84Nov 12, 25$59.61Nov 14, 25$58.06Nov 18, 25$60.17Nov 20, 25$58.42Nov 25, 25$61.69Nov 28, 25$63.47Dec 2, 25$64.45Dec 4, 25$65.25Dec 8, 25$65.62Dec 10, 25$67.56Dec 12, 25$66.96Dec 16, 25$66.37Dec 18, 25$65.91Dec 22, 25$67.43Dec 24, 25$67.42Dec 29, 25$67.47Jan 2, 26$66.54Jan 6, 26$69.89Jan 8, 26$68.43Jan 12, 26$70.98Jan 14, 26$69.70Jan 16, 26$69.54Jan 21, 26$72.11Jan 23, 26$72.86Jan 27, 26$73.67Jan 29, 26$74.00Feb 2, 26$72.53Feb 4, 26$70.82Feb 9, 26$70.16Feb 11, 26$68.15Feb 13, 26$70.02Feb 18, 26$72.80Feb 20, 26$73.08Feb 24, 26$73.09Feb 26, 26$74.38Mar 2, 26$73.78Mar 4, 26$72.90Mar 6, 26$68.10Mar 10, 26$67.79Mar 12, 26$65.26Mar 17, 26$67.32Mar 19, 26$67.27Mar 23, 26$65.94Mar 25, 26$66.84Mar 27, 26$62.25Mar 31, 26$62.80Apr 2, 26$62.22Apr 7, 26$63.11Apr 9, 26$65.68Apr 13, 26$63.12Apr 15, 26$61.54Apr 17, 26$63.98Apr 22, 26$63.41Apr 24, 26$61.57Apr 28, 26$59.32Apr 30, 26$59.55May 4, 26$60.04May 6, 26$60.36May 8, 26$60.61May 12, 26$61.14May 14, 26$57.82May 18, 26$65.09May 20, 26$71.44May 22, 26$72.10May 28, 26$72.34Jun 1, 26$74.87Jun 3, 26$72.77Jun 5, 26$72.86Jun 9, 26$78.19Jun 11, 26$75.25Jun 15, 26$74.22Jun 17, 26$71.23Jun 22, 26$69.07Jun 24, 26$69.75Jun 26, 26$70.14Jul 2, 26$71.25
$54.8452-week range$89.53
Loading valuation history…

Fundamentals

Key fundamentals

$28.4B

Market cap

15.6%

Revenue growth (YoY)

60.0%

Gross margin

$1.1B

Free cash flow (USD)

-$609M

Net debt

Net cash position

-3.6%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$573.3MFY 2017$718.5MFY 2018$1.0BFY 2019$1.5BFY 2020$1.9BFY 2021$2.4BFY 2022$2.9BFY 2023$3.6BFY 2024$4.0BFY 2025$4.7B
$573.3M$4.7B

Free cash flow by year

2016 → 2025

FY 2016$500.0KFY 2017$26.0MFY 2018$56.1MFY 2019$134.5MFY 2020$276.6MFY 2021$53.3MFY 2022$304.7MFY 2023$511.9MFY 2024$630.7MFY 2025$1.1B
$500K$1.1B

Gross margin by year

2021 → 2025

FY 202168.6%FY 202264.7%FY 202363.2%FY 202460.5%FY 202560.0%
68.6%60.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

7

Insider sells · 90 days

Earnings

Last report: 10-Q filed Apr 30, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $297K · 10b5-1 PlanFOLETTA MARK G · Director · $296.5KJun 17, 2026Filing
  • Insider sellInsider Sell $128K · 10b5-1 PlanBrown Michael Jon · EVP Chief Legal Compliance Off · $128.4KJun 17, 2026Filing
  • Insider sellInsider Sell $723K · 10b5-1 PlanColeman Jon · EVP, Chief Commercial Officer · $722.6KJun 5, 2026Filing
  • 8-K eventAnnual Meeting ResultsMay 28, 2026Filing
  • Insider sellInsider Sell $1.9M · 10b5-1 PlanSAYER KEVIN R · Director, Executive Chair · $1.9MMay 26, 2026Filing
  • Insider sellInsider Sell $102K · 10b5-1 PlanBrown Michael Jon · EVP, Chief Legal Officer · $101.8KMay 19, 2026Filing
  • 8-K eventShare Repurchase ProgramMay 15, 2026Filing
  • Insider sellInsider Sell $61K · 10b5-1 PlanHeller Bridgette P · Director · $60.7KMay 14, 2026Filing
  • 8-K eventEarnings ReleaseApr 30, 2026Filing
  • Quarterly report10-Q FiledApr 30, 2026Filing

Questions

Frequently asked questions

What is DexCom, Inc.'s market cap?

DexCom, Inc. (DXCM) has a market capitalization of $28.4B.

What is DXCM's P/E ratio?

DXCM trades at a price-to-earnings ratio of 29.9, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is DXCM's price-to-book (P/B) ratio?

DXCM trades at 10.33 times book value per share.

Are insiders buying DXCM stock?

SEC Form 4 filings show no open-market insider buys at DexCom, Inc. in the last 90 days (7 sells).

Same arena

Related companies in Medical - Devices

RMD

ResMed Inc.

$28.3B

PHG

Koninklijke Philips N.V.

$25.3B

STE

STERIS plc

$20.9B

ZBH

Zimmer Biomet Holdings, Inc.

$16B

SNN

Smith & Nephew plc

$12.7B

ALGN

Align Technology, Inc.

$12.6B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.